5 Therapies|Clear filters
Gemtuzumab ozogamicin (2)
Reg. name: Mylotarg®
Class: Antibody-drug conjugate (ADC)
The Antibody-Drug Conjugate (ADC) gemtuzumab ozogamicin (mylotarg), targets CD33. Since it is a humanized anti-CD33 monoclonal antibody, it is highly specific for targeting leukemic blasts. Mylotarg binds to, and is internalized by, tumor cells expressing CD33. As a result, this ADC can then dispense the anti-tumor antibiotic calicheamicin to CD33-expressing tumor cells.
- Ricart A.D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011 Oct 15;17(20):6417-27. DOI: 10.1158/1078-0432.CCR-11-0486.
MYLOTARG® is indicated for the treatment of newly-diagnosed CD33-positive Acute Myeloid Leukemia (AML) inadults.
MYLOTARG® is indicated for the treatment of relapsed or refractory CD33-positive Acute Myeloid Leukemia (AML) inadults and in pediatric patients 2 years and older.
Arsenic trioxide (1)
Reg. name: Trisenox
The mechanism of action of Arsenic Trioxide (ATO) has not been fully elucidated. However, Kamran Alimoghaddam1 has reported that ATO has induced differentiation in the NB4 cell line. In addition, the TRISENOX® summary of product characteristics states that ATO also causes damage or degradation of the fusion protein Pro-Myelocytic Leukemia/Retinoic Acid Receptor-α (PML/RAR-α).2
- Alimoghaddam K. A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia. Int J Hematol Oncol Stem Cell Res. 2014 Jul 1; 8(3): 44–54.
- TRISENOX® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/28860. [Accessed January 2017].
TRISENOX® is indicated for induction of remission and consolidation in patients with Acute Promyelocytic Leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression